Welcome to our dedicated page for Cassava Sciences SEC filings (Ticker: SAVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cassava Sciences, Inc. (NASDAQ: SAVA) SEC filings page on Stock Titan aggregates the company’s official U.S. Securities and Exchange Commission disclosures, giving investors structured access to its regulatory record. Cassava is a clinical-stage biotechnology company based in Austin, Texas that focuses on developing simufilam, a proprietary, investigational oral small molecule for central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy.
Through this page, readers can review Form 8-K current reports in which Cassava describes material events. Recent 8-K filings detail topics such as a binding term sheet to settle a consolidated securities class action for $31.25 million, the FDA’s decision to place the proposed proof-of-concept clinical trial of simufilam in TSC-related epilepsy on full clinical hold pending additional preclinical data and protocol modifications, and the dismissal of a criminal indictment against a former scientific collaborator. Other 8-Ks furnish earnings press releases, corporate presentations, and announcements regarding board appointments and executive compensation decisions tied to development and budgeting goals.
Investors can also connect these current reports with Cassava’s periodic filings, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which the company references in its risk factor and forward-looking statement discussions. These documents provide broader context on research and development spending, general and administrative expenses, cash and cash equivalents, and recorded loss contingencies related to securities litigation and regulatory matters.
Stock Titan’s platform supplements this raw filing data with AI-powered summaries that highlight the key points in lengthy documents, helping users quickly identify items related to clinical holds, settlement agreements, program discontinuations, and changes in leadership or governance. For those monitoring insider activity, real-time access to Form 4 insider transaction reports and other ownership-related filings is available, allowing a detailed view of equity movements by officers and directors alongside the company’s broader regulatory history.
Filana Therapeutics, Inc. (formerly Cassava Sciences) is a clinical-stage biotech focused on simufilam, an oral small molecule targeting the filamin A protein to treat Tuberous Sclerosis Complex (TSC)-related epilepsy and other CNS disorders. The company has discontinued all Alzheimer’s disease trials after two large Phase 3 studies failed to meet pre-specified efficacy endpoints, though simufilam showed a favorable safety profile in over 2,000 treated patients.
Filana holds a broad patent portfolio on simufilam through at least 2029–2040 and, in February 2025, licensed additional worldwide rights from Yale University, agreeing to up to
The company filed an IND to start a proof-of-concept TSC epilepsy trial, but the FDA placed the proposed study on full clinical hold on
Filana Therapeutics reported a 2025 net loss of $91.0 million, or $1.88 per share, as it repositions around TSC-related epilepsy and other filamin A–driven CNS disorders. The wider loss versus 2024 mainly reflects a $108.1 million non‑recurring gain on warrant liabilities in the prior year.
Cash and cash equivalents were $95.5 million with no debt as of December 31, 2025, after $32.3 million of net cash used in operations. The company estimates cash of $47–$50 million as of June 30, 2026 and expects first-half 2026 operating cash use of $14–$17 million plus a $31.25 million payment tied to an estimated securities litigation loss contingency recorded in 2025.
Filana reduced annual R&D expenses to $26.6 million from $69.6 million, a 62% cut driven by phasing out its Alzheimer’s disease program, and expects its planned TSC-related epilepsy clinical program to cost significantly less. G&A expenses decreased slightly to $68.8 million, reflecting shifting litigation contingencies and higher stock-based compensation. The company is addressing FDA requests in connection with a full clinical hold on its simufilam IND in TSC-related epilepsy and plans to respond as soon as practicable.
Cassava Sciences, Inc. has changed its legal name to Filana Therapeutics, Inc. effective March 10, 2026, through a Certificate of Amendment filed in Delaware. The board also adopted amended and restated bylaws that update provisions on shareholder and board meetings, advance notice, director terms, special meetings, inspectors of election, and uncertificated shares.
Beginning March 11, 2026, the company’s common stock will trade on the Nasdaq Capital Market under the new ticker symbol FLNA. The corporate website has moved from cassavasciences.com to filanatx.com, where investors can access SEC filings, governance documents, and future Code of Conduct updates.
A press release explains that the new Filana Therapeutics identity aligns with a strategic focus on developing investigational therapies that modulate the filamin A protein to treat central nervous system disorders such as TSC-related epilepsy and other diseases linked to filamin A dysregulation.
Cassava Sciences, Inc. reported that the U.S. Department of Justice Fraud Section has closed its inquiry into the company regarding previously disclosed allegations of research misconduct connected to the case United States v. Wang, whose indictment was dismissed with prejudice on October 23, 2025. The company also highlighted that it had earlier resolved negligence-based disclosure charges with the U.S. Securities and Exchange Commission in September 2024 by paying a monetary penalty without admitting or denying the SEC’s allegations. These outcomes conclude the DOJ and SEC investigations of Cassava, allowing management to emphasize a continued focus on developing novel investigational treatments, including simufilam, for central nervous system disorders such as tuberous sclerosis complex-related epilepsy.
Cassava Sciences, Inc. has agreed to a mediated settlement in a federal securities class action pending in the U.S. District Court for the Western District of Texas. Under a binding term sheet, Cassava and its CFO, Eric J. Schoen, will pay
The settlement will provide full and complete releases for Cassava, Mr. Schoen, and two other indemnified officers, with all claims against the non-settling individuals to be dismissed with prejudice upon final court approval. Cassava noted that it had already recorded a
Cassava Sciences, Inc. reports that the U.S. Food and Drug Administration has placed its proposed proof-of-concept clinical trial of simufilam in tuberous sclerosis complex (TSC)-related epilepsy on a full clinical hold. FDA’s letter requires Cassava to provide additional information, including more pre-clinical data, and to modify the trial’s protocol design before the study can proceed. Cassava plans to work expeditiously to address FDA’s comments, but it no longer expects to start this TSC-related epilepsy trial in the first half of 2026 as previously disclosed. The timing for starting a trial will depend on the company’s ability to provide the requested information and on FDA completing its review to the agency’s satisfaction.
Cassava Sciences, Inc. reported that its Board of Directors approved cash bonus awards for calendar 2025 for two named executive officers. The President & Chief Executive Officer, Richard J. Barry, was awarded a cash bonus of $355,000, and the Chief Financial Officer, Eric J. Schoen, was awarded a cash bonus of $215,000, in recognition of their contributions to the company.
For 2025, the Board set performance measures and goals that it described as challenging yet achievable with strong management performance. These goals focus on exploring the use of simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy, building a team with appropriate expertise in TSC-related epilepsy, and managing budgeting and expenses.
Cassava Sciences Inc. (SAVA) reported an insider stock transaction by a director. On 11/24/2025, the director purchased 8,600 shares of Cassava Sciences common stock in an open-market transaction coded as a purchase (code "P"). The shares were acquired at a price of $2.90 per share, and following this transaction, the director beneficially owned 8,600 shares with direct ownership.
Cassava Sciences (SAVA) President and CEO, who is also a director, reported an open-market purchase of common stock. On 11/20/2025, a trust for the reporting person bought 150,000 Cassava shares at a weighted average price of $2.76 per share, with individual trades executed between $2.74 and $2.80.
After this transaction, the trust beneficially owns 938,060 shares of Cassava common stock, reported as indirect ownership. The filing notes that full detail on the number of shares purchased at each price within the range is available upon request.
Cassava Sciences (SAVA) reported an insider stock purchase by its President and CEO, who is also a director. On 11/19/2025, a trust associated with the reporting person bought 73,385 shares of Cassava Sciences common stock in open market transactions at a weighted average price of about $2.75 per share, with individual trade prices ranging from $2.73 to $2.75 per share. After this transaction, the trust beneficially owns 788,060 shares of Cassava Sciences common stock.